1. Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study.
- Author
-
Hu, Jinbo, Zeng, Qinglian, Chen, Xiangjun, Luo, Wenjin, Tang, Ziwei, Mei, Mei, Zhao, Wenrui, Du, Zhipeng, Liu, Zhiping, Li, Qifu, Cheng, Qingfeng, and Yang, Shumin
- Subjects
ARTERIAL diseases ,FOURNIER gangrene ,HYPERALDOSTERONISM ,DISEASE risk factors ,GENOME-wide association studies ,MONOGENIC & polygenic inheritance (Genetics) - Abstract
Background and Aims: Primary aldosteronism (PA) is an adrenal disorder of autonomous aldosterone secretion which promotes arterial injury. We aimed to explore whether PA is causally associated with lower-extremity arterial disease (LEAD). Methods: We included 39,713 patients with diabetes and 419,312 participants without diabetes from UK Biobank. We derived a polygenic risk score (PRS) for PA based on previous genome-wide association studies (GWAS). Outcomes included LEAD and LEAD related gangrene or amputation. We conducted a two-sample Mendelian randomization analysis for PA and outcomes to explore their potential causal relationship. Results: In whole population, individuals with a higher PA PRS had an increased risk of LEAD. Among patients with diabetes, compared to the subjects in the first tertile of PA PRS, subjects in the third tertile showed a 1.24-fold higher risk of LEAD (OR 1.24, 95% CI 1.03–1.49) and a 2.09-fold higher risk of gangrene (OR 2.09, 95% CI 1.27–3.44), and 1.72-fold higher risk of amputation (OR 1.72, 95% CI 1.10–2.67). Among subjects without diabetes, there was no significant association between PA PRS and LEAD, gangrene or amputation. Two-sample Mendelian randomization analysis indicated that genetically predictors of PA was significantly associated with higher risks of LEAD and gangrene (inverse variance weighted OR 1.20 [95% CI 1.08–1.34]) for LEAD, 1.48 [95% CI 1.28–1.70] for gangrene), with no evidence of significant heterogeneity or directional pleiotropy. Conclusions: Primary aldosteronism is genetically and causally associated with higher risks of LEAD and gangrene, especially among patients with diabetes. Targeting on the autonomous aldosterone secretion may prevent LEAD progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF